Upload
riley-pereira
View
217
Download
3
Embed Size (px)
Citation preview
Management of chronic and allergic aspergillosis
David W. DenningDirector, National Aspergillosis CentreUniversity Hospital South Manchester
[Wythenshawe Hospital]The University of Manchester
Antifungal treatments
Treatments availableOralItraconazole capsules ( 3+ formulations)Itraconazole solutionVoriconazole capsulesVoriconazole solutionPosaconazole solution
IntravenousAmBisomeVoriconazoleMicafunginCaspofungin
LocalIntracavitary AmB
Immune therapyGamma interferon (subcutaneous injections)Prednisolone or other steroids
Treatment
Allergic Bronchopulmonary Aspergillosis
Open trial of itraconazole in ABPA - 1991
Before AfterPrednisone (mg/d) 43 24*Total IgE 2462 525*FEV1 1.48 1.79*FVC 2.3 2.9
*p=0.04
Denning et al, Chest 1991; 35:1329
Only 1 patient failed – he had low itraconazole levels.
Stevens et al, New Engl J Med 2000; 342:756
Corticosteroid dependant ABPA with asthmaPhase 1 - 200mg BID v placebo, 16 weeks
Phase II - 200mg daily in all patients, 16 weeks
Stevens et al, New Engl J Med 2000; 342:756
Randomised trial of itraconazole in ABPA
Randomised trial of itraconazole in ABPA
Itra Placebo then ItraPhase 1Overall response 13/28 (46%) 5/27 (19%) p = 0.04Phase 2No prior response 4/13 (31%) 8/20 (40%) NS(n=33)
Stevens et al, New Engl J Med 2000; 342:756
Corticosteroid dependant ABPA with asthmaPhase 1 - 200mg BID v placebo, 16 weeks
Phase II - 200mg daily in all patients, 16 weeks
Number needed to treat = 3.58
Overall 17/28 (61%) response rate
Randomised trial of itraconazole in ABPA
Wark et al, J Clin All Immunol 2003; 111:952
ABPA with asthma, n = 29Phase 1 - 200mg BID v placebo, 16 weeks
Primary outcome measure – Sputum eosinophil count
Eo
sin
op
hili
c ca
tio
nic
pro
tein
P < 0.01
Reduced exacerbation rateNo change in FEV1 or PEF
Retrospective comparison of antifungal treatment of SAFS with
ABPA
Pasquallotto et al, Resp Med 2009 In press
22 patients with SAFS were compared with 11 with ABPA
Severe Asthma and Fungal Sensitisation (SAFS)
www.emphysema-copd.co.uk
Bel EH , Severe asthma. Breath magazine Dec 2006
Severe asthma
Antifungal treatment of severe asthma with fungal sensitisation (SAFS)
Ward et al, J Allergy Clin Immunol 1999;104:541;
11 patients with Trichophyton skin test allergy and moderate/severe asthma,
Rx with fluconazole or placebo for 5 months, then all received fluconazole.
Fluconazole v. placebo at 5 months
• Bronchial hypersensitivity reduced (p = 0.012)• Steroid requirements reduced (p= 0.01)
Peak flow increased in 9/11 at 10 months
Proof of concept RCT of antifungal Rx in SAFS
Denning et al, Am J Resp Crit Care Med 2009; 179:11
Inclusion criteria• Severe asthma [BTS 4 or 5] (ie high dose inhaled steroids, continuous oral steroids for >6 mo, or 4 courses of high dose oral/IV steroids in last 12 months, or 6 courses in last 24 mo.+• Fungal sensitisation (RAST or skin test +ve) to Aspergillus, Cladosporium, Alternaria, Penicillium, Candida, Trichophyton and/or Botrytis
Exclusion criteria• Not ABPA (IgE <1000IU/mL) + -ve Aspergillus precipitins• Recurrent bacterial chest infections (6 weekly)• Prior azole therapy• Cardiac failure• LFTs >3x ULN
Proof of concept RCT of antifungal Rx in SAFS - endpoints
Juniper et al, Thorax 1992;47:76.
Primary endpoint•Improvement in score of Asthma Quality of Life
Questionnaire (AQLQ)
Secondary endpoints• Improvement in weekly peak flow• FEV1 at 4, 8 and 12 months• Exacerbation rate (both total and steroid requiring)• Total IgE• Rhinitis score• Adrenal suppression indices
Proof of concept RCT of antifungal Rx in SAFS - study plan
Denning et al, Am J Resp Crit Care Med 2009; 179:11
Study planRandomised to itraconazole capsules (200mg BID) or placebo for 8 months (concealed by over-encapsulating)
Assessments are regular intervals, including scores, respiratory function, blinded itraconazole levels, LFTs
FU at 4 months post treatment
108 patients planned – 58 enrolled
Denning et al, Am J Resp Crit Care Med 2009; 179:11
Baseline demographics - asthma
Mean (range) or % (no.)
Active(n=29)
Placebo(n=29)
Gender (Male) 48% (14) 48% (14)
Age 49.2 (18,79) 51.7 (19,76)
Severity of asthma (BTS) (>4)
3% (1) 11% (3)
Baseline total serum IgE (IU/L)
212 (24,820) 245 (36,990)
Baseline eosinophilia (>0.4x 109)/L
24% (7) 43% (12)
No. of hospitalisations last 12 months (>1)
39% 17%
Proof of concept RCT of antifungal Rx in SAFS – key results
Denning et al, Am J Resp Crit Care Med 2009; 179:11
Patients enrolled & randomised N = 58
Active (itraconazole) N = 29
Placebo N=1 (p=0.60)
Placebo N = 29
Active N= 3
MITT analysis set (active) N =26 MITT analysis set (placebo) N =28
Withdrawal in <4 weeks
Placebo N=5 (p=0.25)Active N= 8
Withdrawal 4-32 weeks
Per protocol analysis set (active) N= 18
Per protocol analysis set (placebo) N=23
P=0.014AQLQ ∆ = 0.82
P=0.002AQLQ ∆ = 1.18
Proof of concept RCT of antifungal Rx in SAFS – outcomes at 32 weeks MITT
Denning et al, Am J Resp Crit Care Med 2009; 179:11
Mean (95% CI) or % (n) P-value
Active Placebo
Change in AQLQ score +0.85 (0.28, 1.41)
-0.01 (-0.43, 0.42)
0.014
Improvement in AQLQ score of >0.75
54% (14) 18% (5) 0.013
Percentage change in total IgE (IU/L)
-27% (-14%, -38%)
+12% (-5%, +31%)
0.001
Change in FEV1 (L/min) -0.22 (-0.56, 0.11)
-0.02 (-0.16, 0.11)
NS
Change in FEV1 (% predicted)
-3.66 (-9.39, 2.08)
0.13 (-3.67, 3.93)
NS
Change in average PEFR (am)
20.8 (3.5, 38.1)
-5.5 (-21.6, 10.7)
0.028
Change in average PEFR (pm)
16.8 (1.5, 35.2)
8.9 (-33.9, 51.8)
NS
Number needed to treat = 3.22
Proof of concept RCT of antifungal Rx in SAFS – AQLQ change
Denning et al, Am J Resp Crit Care Med 2009; 179:11
P= 0.014
RCT of anti-IgE (omalizumab) v. placebo, moderate and severe asthma
Buhl et al Eur Resp J 2002;20:1088
Improvement in AQLQ
∆ = ~0.4
placebo
omalizumab
Proof of concept RCT of antifungal Rx in SAFS – improvement in rhinitis
Denning et al, Am J Resp Crit Care Med 2009; 179:11
P= 0.013
Relationship of itraconazole drug level to response
Denning et al, Am J Resp Crit Care Med 2009; 179:11
P= 0.22
302520151050
mean itraconazole
4
3
2
1
0
-1
-2
AQ
LQ
ch
ang
e (
wee
k 3
2 lv
cf -
wee
k 1
)
AQLQ change vs itraconazole level
Itraconazole inhaled steroid interaction
• Itraconazole reduces the metabolism of inhaled steroids
• Documented for beclomethasone, fluticasone
• Ciclosenide probably not
• No interaction with prednisolone, dexamethasone, hydrocortisone
• Reduces metabolism of methylprednisolone
• [Voriconazole reduces prednisolone metabolism, but probably no interaction with inhaled steroid]
Itraconazole inhaled steroid interaction in 50% of patients, with complete suppression of
cortisol
AQLQ improvements identical in those with this interaction and those without
Denning et al, Am J Resp Crit Care Med 2009; 179:11
Management of inhaled steroids in patients on itraconazole
• Start itraconazole without changing steroid doses
• At one month, attempt steroid reduction, first prednisolone, then inhaled steroids + check random cortisol
• Reduce inhaled steroid by 50% initially for ~1 month.
• At month 2, if asthma well (possibly better) controlled, attempt a second inhaled steroid reduction. If low cortisol, do short synacthen test (timing in day not important – increment the key result)
• If adrenals functional, and asthma well controlled, consider switch to ciclosonide
• If poor adrenal reserve, assess total steroid needs, and ensure patient can be supported with oral steroids if unwell
Randomised studies of antifungals and ABPA and/or
asthmaDisease Antifungal,
durationBenefit? Author, year
ABPA Natamycin inh, 52 wks
No Currie, 1990
ABPA Itraconazole, 32 wks
Yes Stevens, 2000
ABPA Itraconazole, 16 wks
Yes Wark, 2003
“Trichophyton” asthma Fluconazole, 20 wks
Yes Ward, 1999
SAFS Itraconazole, 32 wks
Yes Denning, 2009
Chronic Pulmonary Aspergillosis
Antifungal therapy
IDSA guidelines. Walsh et al. Clin Infect Dis 2008;46:327
Treatment of chronic cavitary pulmonary aspergillosis
Denning DW et al, Clin Infect Dis 2003; 37:S265; Jain & Denning. J Infect 2006;52:e133-7.
Treatment No of courses Stable or improved (%)
Treatment failure /
progression
Toxicity
Itraconazole primary therapy
17 12 (71) 5 3
Voriconazole 17 9/11 (82) 2 12
Amphotericin B IV
11 9 (82) 2 7
Gamma IFN with itraconazole
3 3 0 3
Itraconazole maintenance after AmB IV
6 6 0 0
Felton, Clin Infect Dis 2010; 51:1383.
Nivoix et al, Clin Infect Dis 2008;47:1176
Impact of voriconazole in real life
weeks
Effect of voriconazole on CPA
Jain & Denning J Infect 2006; 52:e133-7
16 patients, all failing or intolerant of itraconazole
5 patients were able to take >3 months RxSymptom response
Cough 3/11 (27%) sputum 6/11 (55%) chest pain 4/10 (40%) breathlessness 4/11 (36%) well being 6/11 (55%) weight 4/10 (40%)
Parameters of response in CPA (with voriconazole)
Jain & Denning J Infect 2006; 52:e133-7
CPA and voriconazole Rx
Sambatakou et al, Am J Med 2006:119:527.e17-24
CPA and voriconazole Rx
Camuset et al, Chest 2007:131:1435
9 patients with chronic cavitary pulmonary aspergillosis15 with chronic necrotising pulmonary aspergillosis
13/24 (54%) primary therapy with voriconazole3 intolerant of voriconazoleMedian duration of Rx 6.4 mos (4-36)
Time to initial response with posaconazole therapy
6 months 12 months
Mean
95% confidence interval
Felton et al. Clin Infect Dis 2010. In press.
Judging response to treatmentClinicalLess tiredBetter appetiteWeight gainLess coughingLess productiveLess coughing of bloodGenerally feeling better
Judging response to treatment
Al-shair et al, AAA 2012 poster
ClinicalLess tiredBetter appetiteWeight gainLess coughingLess productiveLess coughing of bloodGenerally feeling better
Judging response to treatmentClinicalLess tiredBetter appetiteWeight gainLess coughingLess productiveLess coughing of bloodGenerally feeling better
TestsPlasma viscosity and C reactive protein (CRP) fallingAspergillus precipitins falling (slow)Total IgE fallingChest Xray shows no new cavities, and eventually thin walled
cavities
Randomised controlled open comparison of micafungin and voriconazole for chronic
pulmonary aspergillosis
Kohno et al. J Infect Dis 2010;61:410
Micafungin 150-300mg/d versus voriconazole 12 ➞ 8mg/Kg/d107 patients with CPA 2-4 weeks treatment
Chronic cavitary pulmonary aspergillosis (CCPA) – coughing up blood (haemoptysis)
Wythenshawe Hospital
CPA and haemoptysis• Minor haemoptysis common
• Manageable with tranexamic acid orally
• Bronchial embolisation a good option, if vessel can be embolised & patient can lie flat for 2-3 hours
Technique 1
• Must lie flat– optimise respiratory function– oxygen– NIPPI– Consider anaesthetic support
• Femoral access• Flush aortogram or pre-op CT• 4F systems• Microcatheters
Technique 2
• Embolic agents– PVA/ microspheres– Avoid liquids– Avoid coils
• Embolise bronchial arteries• Look for accessory feeders if recurrent• Consider closure device• May need multiple procedures
Dry microspheres, made up in saline and radiocontrast material
Results of bronchial artery embolisation
• 50% patients have multiple blood supply• Control of haemorrhage in >90% patients• 30-50% rebleed rate at 3 years• Mean rebleed free interval 9 months
• Serisli et al Int Angio 2008;27:319-28
Patient PA
Nov 2008
Nov 2009
Jan 2010Posaconazole Rx
April 2010Posaconazole
Rx
Nov 2010Stopped posaconazole
Patient PA
Nov 2010Stopped posaconazole
Aug 2011No therapy
Dec 2011No therapy
Upper right bronchial artery embolisation
Pre Post
Bronchial artery embolisation (2)
Pre Post
Angiographic signs of bronchial bleeding
• Direct (rare)– Extravasation of contrast– Thrombosis of branch vessels
• Indirect– Hypertrophy of parent vessel– Neovascularisation– Aneurysm formation– Systemic to pulmonary shunting
Bronchial artery embolisation (3)
Pre Post
Intercostal artery embolisation
Pre Post
Intercostal artery embolisation (2)
Pre Post
Thyrocervical axis artery embolisation
Pre Post
Internal mammary artery embolisation
PreNote the large coil inferiorly in the internal mammary artery which prevents embolisation of the coeliac axis inadvertently
Post
Lateral thoracic artery embolisation
PreNote the smaller catheter inside the larger one
Post
Subclavian artery embolisation
PreNote the second catheter within the lumen of the R subclavian artery
Post
Bronchial Embolisation - Complications
• Minor - common– fever– pleuritic chest pain– dysphagia
• Major - rare– bronchial infarction– bronchial stenosis– Broncho oesophageal fistula– paraplegia
• Chemotoxic• embolic
– TIA/stroke
Bronchial Embolisation avoiding the anterior spinal artery
Chronic cavitary pulmonary aspergillosis Chronic cavitary pulmonary aspergillosis an example of radiographic failurean example of radiographic failure
Patient SSApril 2004
www.aspergillus.man.ac.uk
Patient SSJuly 2004, despite receiving itraconazole for 3 months
Stopping treatment after good response in CPA?
Chronic cavitary pulmonary aspergillosis
Patient RWJune 2002
Stable, asymptomatic, normal inflammatory markers, just detectable Aspergillus precipitins
Itraconazole stopped after 5 years
www.aspergillus.org.uk
Chronic cavitary pulmonary aspergillosis - relapse
Patient RWJanuary 2003
Marked change, with new cough, weight loss, ↑CRP/ESR and ↑Aspergillus precipitins
Itraconazole restarted
www.aspergillus.org.uk
Patient RWSeptember 1992
Chronic cavitary pulmonary Chronic cavitary pulmonary aspergillosisaspergillosis
www.aspergillus.man.ac.uk
Patient RWJune 2003
CPA treatment - principles• Important defects in innate immunity so long term (i.e. life-long) antifungal treatment, if possible• Some patients appear not to progress, but should to be kept under observation, as progression may be subclinical• Minimise other causes of lung infection with immunisation and antibiotics
• Itraconazole, voriconazole and posaconazole all effective, but adverse events
• Amphotericin B useful for oral azole therapy and failure
• Gamma IFN helpful in some cases
• Monitor for azole resistance